STAAR Surgical (STAA)
(Delayed Data from NSDQ)
$32.06 USD
-0.06 (-0.19%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $32.04 -0.02 (-0.06%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$32.06 USD
-0.06 (-0.19%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $32.04 -0.02 (-0.06%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Zacks News
Analysts Estimate Staar Surgical (STAA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Staar Surgical (STAA) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of -25.00% and -6.40%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Staar Surgical (STAA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STAAR Surgical (STAA) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
STAAR Surgical's (STAA) ICL line of products is likely to have boosted Q2 performance amid the coronavirus pandemic.
Analysts Estimate Staar Surgical (STAA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STAAR Surgical (STAA) Jumps: Stock Rises 8.9%
by Zacks Equity Research
STAAR Surgical (STAA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Staar Surgical (STAA) Q1 Earnings Lag Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of -42.86% and 5.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Staar Surgical (STAA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Staar Surgical (STAA) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 33.33% and 4.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Staar Surgical (STAA) Beats Q2 Earnings Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 40.00% and -1.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Herman Miller, Clean Harbors, Great Lakes Dredge & Dock and STAAR Surgical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Herman Miller, Clean Harbors, Great Lakes Dredge & Dock and STAAR Surgical
4 Stocks to Buy From Sectors With Top Job Gains
by Zacks Equity Research
New job additions across business services, construction and healthcare were prominent in April.
Zacks.com featured highlights include: Ralph Lauren, Nu Skin, Tilly's, Centene and STAAR
by Zacks Equity Research
Zacks.com featured highlights include: Ralph Lauren, Nu Skin, Tilly's, Centene and STAAR
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Analysts Estimate Staar Surgical (STAA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Has STAAR Surgical (STAA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (STAA) Outperforming Other Medical Stocks This Year?
4 Healthcare Stocks That Popped More Than 100% in 2018
by Sapna Bagaria
Players in the Healthcare sector gained from aging population, expanding government business, technological investment, strong demand for its product and services and industry consolidation.
Here's Why You Should Buy Express Scripts (ESRX) Stock Now
by Zacks Equity Research
Strong demand for Express Scripts' (ESRX) solutions like SafeGuardRx, 90-day supply for chronic medications, exclusive Accredo Specialty Pharmacy and advanced opioid solutions buoy optimism.
4 Medical Device Stocks That More Than Doubled in 2018
by Sweta Jaiswal
Here are four medical device stocks which have performed really well in 2018 and should be on investors' radar next year as well.
Here's Why You Should Hold Allscripts Stock in Your Portfolio
by Zacks Equity Research
Allscripts (MDRX) has been winning contracts in the Sunrise EHR platform; competition stiff.
Express Scripts Announces 3-Year Agreement With Walmart
by Zacks Equity Research
Express Scripts (ESRX) and Walmart (WMT) collaborate to increase affordable access of the expensive prescription drugs for insured and uninsured patients.
BD Gets Enterprise Level Cybersecurity Assessment From UL
by Zacks Equity Research
BD (BDX) receives UL CAP for BD FACSLyric flow cytometer with BD FACSuite Clinical software.
Here's Why Investors Should Hold Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) gains from solid prospects in the SET Pulse Oximeter platform. However, cutthroat competition in the MedTech space is likely to hurt the stock.